Claudia Diefenbach

Biberach An Der Riss, BW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Circulating biomarkers in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial.

Circulating biomarkers in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial.

Journal: Annals of the rheumatic diseases
Published: January 29, 2026

Circulating biomarkers in subjects with progressive pulmonary fibrosis: data from the INBUILD trial.

Circulating biomarkers in subjects with progressive pulmonary fibrosis: data from the INBUILD trial.

Journal: ERJ open research
Published: February 03, 2025

Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis.

Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis.

Journal: ERJ open research
Published: June 19, 2024

Novel cathepsin C inhibitor, BI 1291583, intended for treatment of bronchiectasis: Phase I characterization in healthy volunteers.

Novel cathepsin C inhibitor, BI 1291583, intended for treatment of bronchiectasis: Phase I characterization in healthy volunteers.

Journal: Clinical and translational science
Published: May 16, 2024

The preclinical and phase 1 development of the novel oral cathepsin C inhibitor BI 1291583.

The preclinical and phase 1 development of the novel oral cathepsin C inhibitor BI 1291583.

Journal: ERJ open research
Published: September 29, 2023

Baseline characteristics from a 3-year longitudinal study to phenotype subjects with COPD: the FOOTPRINTS study.

Baseline characteristics from a 3-year longitudinal study to phenotype subjects with COPD: the FOOTPRINTS study.

Journal: Respiratory research
Published: July 31, 2023

Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trial.

Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trial.

Journal: ERJ open research
Published: May 22, 2023

A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf.

A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf.

Journal: ERJ open research
Published: November 18, 2022

Nintedanib modulates type III collagen turnover in viable precision-cut lung slices from bleomycin-treated rats and patients with pulmonary fibrosis.

Nintedanib modulates type III collagen turnover in viable precision-cut lung slices from bleomycin-treated rats and patients with pulmonary fibrosis.

Journal: Respiratory research
Published: November 26, 2021

FOOTPRINTS study protocol: rationale and methodology of a 3-year longitudinal observational study to phenotype patients with COPD.

FOOTPRINTS study protocol: rationale and methodology of a 3-year longitudinal observational study to phenotype patients with COPD.

Journal: BMJ open
Published: March 23, 2021

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.

Journal: The Lancet. Respiratory medicine
Published: March 18, 2019

Lung tissue destruction by proteinase 3 and cathepsin G mediated elastin degradation is elevated in chronic obstructive pulmonary disease.

Lung tissue destruction by proteinase 3 and cathepsin G mediated elastin degradation is elevated in chronic obstructive pulmonary disease.

Journal: Biochemical and biophysical research communications
Published: July 04, 2018
Showing 1-12 of 14

Last Updated: 09/26/2026